Back to today’s briefing

Story perspectives

Myriad Genetics Shares Surge After CEO Change and Upgrade

3/13/2025

38 5

Summary

Story summary

Myriad Genetics Inc (NASDAQ:MYGN) saw its shares surge by 9.8% to $11.25 after Piper Sandler upgraded the stock to "overweight," setting a new price target of $12.50. This positive shift comes on the heels of new CEO Sam Raha's appointment, igniting optimism among analysts who foresee a potential rise to a consensus target of $17.41.

1 of 1

Story summary

Myriad Genetics Inc (NASDAQ:MYGN) saw its shares surge by 9.8% to $11.25 after Piper Sandler upgraded the stock to "overweight," setting a new price target of $12.50. This positive shift comes on the heels of new CEO Sam Raha's appointment, igniting optimism among analysts who foresee a potential rise to a consensus target of $17.41.